Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

May 4, 2026

Study Completion Date

December 4, 2027

Conditions

Marginal Zone Lymphoma(MZL)

Interventions

DRUG

Orelabrutinib

150mg po

DRUG

rituximab

375mg/m\^2, intravenous

DRUG

Cyclophosphamide

750mg/m\^2

DRUG

Vincristine

1.4mg/m\^2

DRUG

Prednisone tablet

60mg/m\^2

Trial Locations (1)

RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

All Listed Sponsors

lead

Fei Li

OTHER